Study Hopes to Resolve Questions About Management of Pre-Cancers of the Breast
As physicians and researchers question whether certain treatments for early signs of breast cancer are necessary, the first large US study will seek to determine the best way to manage ductal carcinoma in situ.
Marketplace Health Insurance Options for HIV-Positive People
For HIV-positive patients, cost considerations take on added importance because of the expensive antiretroviral prescription medications. As such, assessing premiums alone may not provide an accurate measure of plan affordability for HIV-positive patients.
High Risks, High Costs Associated With Febrile Neutropenia in Metastatic Cancer
Data from 2 large studies of patients with metastatic disease who underwent myelosuppressive chemotherapy found that febrile neutropenia occurred in approximately 13% to 21% of patients. Associated costs of febrile neutropenia were found to range from $16,000 to $19,000 per episode for most hospitalized patients.
Cost Sharing for Marketplace Enrollees Held Steady in 2015
Cost sharing for marketplace plans remained essentially unchanged from 2014 to 2015, but stable premiums during the period do not reflect the greater costs borne by enrollees, according to a report from The Commonwealth Fund.
Aspirin May Lower Breast Tissue Density, Lead to Early Detection of Cancer
New data does not support the idea that aspirin has protective qualities and “down-the-road” benefits for breast cancer patients. It may, however, help reduce breast density and improve earlier detection of some breast cancers.